New Risk • 13h
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳158m revenue, or US$1.3m). Market cap is less than US$100m (৳1.87b market cap, or US$15.2m). Reported Earnings • Jun 02
Third quarter 2026 earnings released: EPS: ৳0.40 (vs ৳0.85 in 3Q 2025) Third quarter 2026 results: EPS: ৳0.40 (down from ৳0.85 in 3Q 2025). Revenue: ৳28.3m (down 48% from 3Q 2025). Net income: ৳964.0k (down 53% from 3Q 2025). Profit margin: 3.4% (down from 3.8% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Apr 27
Ambee Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 29, 2026 Ambee Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 29, 2026 공시 • Jan 25
Ambee Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026 Ambee Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026 공시 • Nov 10
Ambee Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 12, 2025 Ambee Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 12, 2025 공시 • Nov 04
Ambee Pharmaceuticals PLC announces Annual dividend, payable on January 18, 2026 Ambee Pharmaceuticals PLC announced Annual dividend of BDT 1.0000 per share payable on January 18, 2026, ex-date on November 23, 2025 and record date on November 20, 2025. 공시 • Nov 03
Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025 Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 18, 2025, at 11:00 Central Asia Standard Time. Location: 184/1, tejgaon industrial area, dhaka-1208, Bangladesh 공시 • Oct 27
Ambee Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 30, 2025 Ambee Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 30, 2025 공시 • Apr 24
Ambee Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 27, 2025 Ambee Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 27, 2025 공시 • Jan 16
Ambee Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 22, 2025 Ambee Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 22, 2025 Declared Dividend • Nov 13
Dividend of ৳1.00 announced Shareholders will receive a dividend of ৳1.00. Ex-date: 3rd December 2024 Payment date: 23rd January 2025 Dividend yield will be 0.1%, which is lower than the industry average of 2.5%. 공시 • Nov 12
Ambee Pharmaceuticals PLC to Report Q1, 2025 Results on Nov 14, 2024 Ambee Pharmaceuticals PLC announced that they will report Q1, 2025 results on Nov 14, 2024 공시 • Nov 11
Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024 Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2024, at 11:00 Central Asia Standard Time. Location: industrial area, dhaka-1208, Bangladesh 공시 • Nov 06
Ambee Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Nov 10, 2024 Ambee Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Nov 10, 2024 New Risk • Jun 30
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Revenue is less than US$5m (৳205m revenue, or US$1.7m). Market cap is less than US$100m (৳1.80b market cap, or US$15.3m). Reported Earnings • Jun 27
Third quarter 2024 earnings released: EPS: ৳0.80 (vs ৳0.69 in 3Q 2023) Third quarter 2024 results: EPS: ৳0.80 (up from ৳0.69 in 3Q 2023). Revenue: ৳45.3m (down 8.2% from 3Q 2023). Net income: ৳1.91m (up 15% from 3Q 2023). Profit margin: 4.2% (up from 3.4% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. 공시 • Apr 23
Ambee Pharmaceuticals PLC to Report Q3, 2024 Results on Apr 28, 2024 Ambee Pharmaceuticals PLC announced that they will report Q3, 2024 results on Apr 28, 2024 New Risk • Feb 11
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (20% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (৳209m revenue, or US$1.9m). Market cap is less than US$100m (৳1.93b market cap, or US$17.6m). Reported Earnings • Feb 07
Second quarter 2024 earnings released: EPS: ৳0.60 (vs ৳0.35 in 2Q 2023) Second quarter 2024 results: EPS: ৳0.60 (up from ৳0.35 in 2Q 2023). Revenue: ৳58.5m (up 2.7% from 2Q 2023). Net income: ৳1.45m (up 72% from 2Q 2023). Profit margin: 2.5% (up from 1.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. 공시 • Jan 22
Ambee Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024 Ambee Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024 Upcoming Dividend • Nov 19
Upcoming dividend of ৳1.50 per share at 0.2% yield Eligible shareholders must have bought the stock before 26 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%). 공시 • Nov 07
Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023 Ambee Pharmaceuticals PLC, Annual General Meeting, Dec 14, 2023, at 11:00 Bangladesh Standard Time. 공시 • Oct 28
Ambee Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Nov 02, 2023 Ambee Pharmaceuticals PLC announced that they will report fiscal year 2023 results on Nov 02, 2023 New Risk • Oct 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (৳191m revenue, or US$1.7m). Market cap is less than US$100m (৳1.99b market cap, or US$18.0m). New Risk • Jul 13
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 23% per year over the past 5 years. High level of non-cash earnings (26% accrual ratio). Minor Risks Revenue is less than US$5m (৳191m revenue, or US$1.8m). Market cap is less than US$100m (৳1.29b market cap, or US$11.9m). Reported Earnings • Jul 11
Third quarter 2023 earnings released: EPS: ৳0.69 (vs ৳0.40 in 3Q 2022) Third quarter 2023 results: EPS: ৳0.69 (up from ৳0.40 in 3Q 2022). Revenue: ৳49.4m (up 30% from 3Q 2022). Net income: ৳1.67m (up 74% from 3Q 2022). Profit margin: 3.4% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 17
Second quarter 2023 earnings released: EPS: ৳0.35 (vs ৳0.24 in 2Q 2022) Second quarter 2023 results: EPS: ৳0.35 (up from ৳0.24 in 2Q 2022). Revenue: ৳56.9m (down 10.0% from 2Q 2022). Net income: ৳841.0k (up 49% from 2Q 2022). Profit margin: 1.5% (up from 0.9% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year. Reported Earnings • Dec 11
Full year 2022 earnings released: EPS: ৳3.36 (vs ৳5.42 loss in FY 2021) Full year 2022 results: EPS: ৳3.36 (up from ৳5.42 loss in FY 2021). Revenue: ৳181.0m (up 83% from FY 2021). Net income: ৳8.06m (up ৳21.1m from FY 2021). Profit margin: 4.5% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. 공시 • Nov 23
Ambee Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022 Ambee Pharmaceuticals Limited announced the board of directors has recommended 10% cash dividend for the year ended June 30, 2022. Date of AGM is December 31, 2022. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Jul 13
Ambee Pharmaceuticals Limited Appoints Ms. Kazi Tanzzina Ferdous as Managing Director Ambee Pharmaceuticals Limited announced the appointment of Ms. Kazi Tanzzina Ferdous as the Managing Director of the Company. Reported Earnings • May 29
Third quarter 2022 earnings released: EPS: ৳0.40 (vs ৳0.30 in 3Q 2021) Third quarter 2022 results: EPS: ৳0.40 (up from ৳0.30 in 3Q 2021). Revenue: ৳38.0m (down 3.6% from 3Q 2021). Net income: ৳961.0k (up 34% from 3Q 2021). Profit margin: 2.5% (up from 1.8% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 2 independent directors (7 non-independent directors). Independent Director Shafiqul Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Dec 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: ৳5.42 loss per share (down from ৳1.52 profit in FY 2020). Revenue: ৳99.0m (down 65% from FY 2020). Net loss: ৳13.0m (down 458% from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 27
Full year 2020 earnings released: EPS ৳1.52 (vs ৳1.40 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ৳285.3m (down 11% from FY 2019). Net income: ৳3.64m (up 8.0% from FY 2019). Profit margin: 1.3% (up from 1.0% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 23
Upcoming dividend of ৳1.50 per share Eligible shareholders must have bought the stock before 29 June 2021. Payment date: 12 August 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (2.8%). Lower than average of industry peers (1.5%). Is New 90 Day High Low • Feb 04
New 90-day low: ৳417 The company is down 9.0% from its price of ৳459 on 05 November 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 15% over the same period. Is New 90 Day High Low • Jan 20
New 90-day low: ৳430 The company is down 9.0% from its price of ৳474 on 22 October 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 20% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: ৳441 The company is down 1.0% from its price of ৳446 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. 
